Rheumatoid arthritis (RA) is an inflammatory disease that cause chronic pain, disability and joint destruction. The present placebo controlled randomized study aimed to evaluate the efficacy of a novel hydrogenated curcuminoid formulation-CuroWhite™, in rheumatoid arthritis (RA) patients. Twenty four RA patients were randomized in 1:1:1 ratio to receive 250 mg, 500 mg CuroWhite or placebo as one capsule a day, over a period of three months. Improvement in the ACR response, changes in disease activity assessed using the DAS 28 score, change in physical function assessed on change in ESR, CRP, RF values were evaluated before and after the study. Results suggested that patients who received CuroWhite both low and high doses reported statistically significant changes in their clinical symptoms towards end of the study when compared with placebo. There were significant changes in DAS28 (50-64%) VAS (63-72%) ESR (88-89%), CRP (31-45%) RF (80-84%) values and ACR response for CuroWhite groups in comparison with placebo. Thus, CuroWhite acts as the analgesic and anti-inflammatory product for management of RA by the reduction of the inflammatory action which was confirmed by improvement in ESR, CRP, VAS, RF, DAS-28 and ACR responses. CuroWhite was significantly effective against RA with highly safe without serious side effects and well tolerated.
Keywords: ACR response; CuroWhite; DAS-28; Hydrogenated curcuminoids; Rheumatoid arthritis.